Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

The Food and Drug Administrating announced that to “avoid unnecessary disruption to patient treatment,” the agency does not intend to take ...

The shortage of Novo Nordisk’s (NVO) blockbuster diabetes and weight-loss drugs is officially over, according to the U.S.

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, a declaration that will curtail ...

Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...

Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.

The U.S. Food and Drug Administration declared that the shortage of Novo Nordisk's weight-loss medications Wegovy and Ozempic has been resolved, according to its website. The FDA announcement confirms ...

The resolution could potentially restrict how telehealth programs offer cheaper versions known as compounded drugs ...

A shortage of Danish drugmaker Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved, ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.